The biotech investments turning health into newfound wealth.

Healthcare and medical research is one of Australia’s strongest research areas and of enormous global importance as the world’s population – in particular the ageing population – continues to grow.

The Australian life sciences ecosystem is worth more than $8 billion in annual revenue with annual growth projected at 3% from 2021-2026.

Our impressive list of medical discoveries and developments include the bionic ear, spray on skin and the cervical cancer vaccine.

In 2020, when the world was brought to a standstill by the Covid-19 pandemic, the worldwide race to find a preventative vaccine and effective treatment began. All eyes were on the biotechnology sector with Pfizer, AstraZeneca, and Moderna becoming household names.

There’s a growing number of small and midcap biotechs on their way up through the ranks. In this guide, you’ll find profiles for ASX-listed companies, expert analysis, and even a few tips on which ones to watch.

Over the coming months we will publish more guides in the series with a view to educating readers of Stockhead and The Australian about the most exciting and emerging sectors on the ASX.

And it’s free. What are you waiting for?

Open larger version Download PDF